Crohn Disease

Latest Articles

De-Escalation and Discontinuation of Biologics in IBD: What to Consider

By

C. Andrew Kistler, MD, PharmD

Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.

Bacterial and Fungal Profiles Estimate Infliximab Response in Patients With IBD

By

Virginia A. Schad, PharmD, RPh

A team of investigators sought to determine the influence of infliximab on gut bacterial and fungal composition in patients with inflammatory bowel disease.

The Crohn’s Anal Fistula Quality of Life Scale: A Patient-Reported Outcome Measure

By

Virginia A. Schad, PharmD, RPh

As Crohn disease perianal fistulas often do not respond to available treatments, researchers developed a patient-derived quality-of-life tool to evaluate the impact of the condition on patients.

Clinical Remission Observed With Risankizumab in Crohn Disease Trials

By

Brian Park, PharmD

Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.

Improved Psychological Support Is Needed After Stoma Surgery

By

Jessica Nye, PhD

Interview study identified categories in which improved psychological support services are needed for these patients.

Socioeconomic Status Influences Inflammatory Bowel Disease Outcomes

Lower socioeconomic status is associated with worse outcomes for inflammatory bowel disease.

CONUT Score Effectively Stratifies Risk for Postoperative Complications in Crohn Disease

By

Jessica Nye, PhD

Investigators assessed the Controlling Nutritional Status’ (CONUT’s) efficacy in predicting postoperative complications in patients with Crohn disease.

Expanded Insight Guides Therapeutic Strategy in IBD Amid COVID-19

By

Rachel Narozniak, MA

Although the emergence of COVID-19 initially called the continuation of inflammatory bowel disease (IBD) therapy into question, treatment has proceeded — albeit with added considerations.

A History of Depression and Gastrointestinal Symptoms May Predict Risk for Subsequent IBD

By

Jessica Nye, PhD

Investigators assessed whether depression, adjusted for preexisting gastrointestinal symptoms, is associated with subsequent inflammatory bowel disease.

Study Identifies Novel Plasma Proteomic Biomarkers for Crohn Disease Complications

By

Virginia A. Schad, PharmD, RPh

Investigators used a machine learning strategy to seek out plasma protein biomarkers for stricturing and penetrating complications.

Marked Decline in 5-Year Surgery Rates Seen for Ulcerative Colitis, Crohn Disease

By

Emily Pond

Investigators analyzed the surgical risk for ulcerative colitis and Crohn disease in contemporary, population-based inception cohorts vs 20th century cohorts.

Biologics May Reduce Surgery Rates in CD, UC

By

Emily Pond

The investigators used a commercial database containing electronic health record data from 26 major United States healthcare systems to assess the effect of biologics on surgery rates in the IBD setting.

NIH: Immune Modulators to Be Investigated for COVID-19

By

Brian Park, PharmD

The NIH-led trial will assess 3 drugs: infliximab, a tumor necrosis factor blocker, abatacept, a selective T cell costimulation modulator, and cenicriviroc, an investigational immunomodulator that blocks 2 chemokine receptors, CCR2 and CCR5.

Managing Inflammatory Bowel Disease in the Elderly: A Clinical Practice Update From the AGA

By

Colby Stong

Managing for elderly patients with inflammatory bowel disease involves unique challenges in both diagnosis and therapeutic decision making.

Multiomic Study Investigates Mucosal Healing in Pediatric Crohn Disease

By

Emily Pond

The goal of this study was to describe changes in the microbiota, metabolome, and protease activity related to mucosal healing in established pediatric Crohn disease.

Molecular Evidence Suggests Similar Treatment Targets for IBD or COVID-19

By

Jessica Nye, PhD

Therapies for the treatment of inflammatory bowel disease may have a potential use in patients with COVID-19.

Vedolizumab Is Safe Long-Term for Ulcerative Colitis and Crohn Disease

By

Colby Stong

Alimentary Pharmacology and Therapeutics reports on the final results from the GEMINI long-term safety study on vedolizumab, a gut-selective α4 β7 integrin antibody approved for moderately to severely active ulcerative colitis and Crohn disease.

Pro-Inflammatory Diets May Increase Risk for Crohn Disease

By

Colby Stong

An analysis of 3 large prospective cohorts examined the association between dietary patterns with high inflammatory potential and increased risks for Crohn disease and ulcerative colitis.

Crohn Disease: Steroid IV Therapy Boosts Risk for Short Bowel Syndrome

By

Brandon May

Researchers analyzed independent risk factors for short bowel syndrome in patients with Crohn disease in an effort to develop preventive strategies.

Inflammatory Bowel Disease and the Risk of Extraintestinal Cancers

By

C. Andrew Kistler, MD, PharmD

A team of investigators conducted a systematic review and meta-analysis to assess the risk of extraintestinal cancer in patients with inflammatory bowel disease.